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We studied the nature and extent of comorbidity of chronic frequent headache
(CFH) in the general population and the influence of CFH and comorbidity on
quality of life. Subjects with CFH (headache on >14 days/month) were identified
in a general health survey. We sent a second questionnaire including questions
on comorbidity and quality of life to subjects with CFH and subjects with
infrequent headache (IH) (1–4 days/month). We recoded comorbidity by using
the Cumulative Illness Rating Scale (CIRS) and measured quality of life with the
RAND-36, a Dutch version of Short Form-36. CFH subjects (n = 176) had higher
comorbidity scores than the IH subjects (n = 141). Mean CIRS scores were 2.94 for
CFH and 1.55 for IH [mean difference 1.40, 95% confidence interval (CI) 0.91,
1.89]. The mean number of categories selected was 1.92 in CFH and 1.10 in IH
(mean difference 0.82, 95% CI 0.54, 1.11). Fifty percent of CFH subjects had a
comorbidity severity level of at least 2, indicating disorders requiring daily
medication, compared with 28% of IH subjects (mean difference 22%, 95% CI 12,
33). CFH subjects had more musculoskeletal, gastrointestinal, psychiatric and
endocrine/breast pathology than IH subjects. Quality of life in CFH subjects was
lower than that of IH subjects in all domains of the RAND-36. Both headache
frequency and CIRS score had a negative influence on all domains. We conclude
that patients with CFH have more comorbid disorders than patients with
infrequent headaches. Many CFH patients have a comorbid chronic condition
requiring daily medication. Both high headache frequency and comorbidity
contribute to the low quality of life in these patients. Chronic daily headache,
comorbidity, headache, medication overuse, quality of life
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Introduction
Epidemiological studies on comorbidity of headache
disorders have focused primarily on psychiatric
disorders. Migraine has been repeatedly found to be
associated with major depression and anxiety disor-
ders (1–4). Breslau et al. found a bi-directional rela-
tionship between migraine and major depression; a
history of major depression is a risk factor for
migraine and migraine increases the risk for major
depression (3). They suggested that shared underly-
ing factors explain the co-occurrence of the two
disorders, rather than major depression being a psy-
chological response to recurrent severe headaches.
Chronic frequent headache (CFH), also known as
chronic daily headache, is defined as headache on
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>14 days per month for at least 3 months. Around
4% of the general population suffer from CFH (5, 6).
In headache clinics, the majority of patients with
CFH have a comorbid psychiatric disorder (7–9).
The most commonly reported disorders are major
depression and generalized anxiety disorder, fol-
lowed by panic disorder and phobias. High head-
ache frequency and chronic substance use are
associated with higher scores on anxiety and
depression scales (10, 11). In a general population
sample, aged >64 years, a high score on a depres-
sion scale was associated with CFH and subjects
with CFH were at increased risk of major depres-
sion at follow-up (12).
Few studies have explored comorbidity of
headache with somatic disorders. Associations of
migraine with epilepsy, stroke, asthma and chronic
musculoskeletal pain have been reported (13–15).
CFH has been associated with allergies, asthma,
hypothyroidism, hypertension, sleep disorders and
fibromyalgia (16, 17). These studies were conducted
in headache clinics, which might have led to an
overestimation of associations, because referred
patients may represent a selected, difficult to treat
population. To avoid this bias, population-based
studies are preferred.
The overall comorbidity of CFH in the general
population has not been studied systematically.
Co-occurrence of diseases can complicate diagnosis,
due to symptomatic overlap of the two conditions,
and can have important implications for treatment.
Moreover, comorbidity can have a negative influence
on quality of life. Quality of life is reduced
in subjects with CFH and is greatly influenced
by anxiety and depressive disorders (18–20). We
studied the nature and extent of comorbidity in CFH
patients in the general population and examined the
influence of CFH and comorbidity on quality of life.
Methods
We conducted a general health survey amongst all
persons, aged 25–55 years, registered at 16 general
practices in the province of South-Holland in the
Netherlands in 2003. This sample represents the
general population because in the Netherlands all
individuals are registered at a general practice.
The study design and methodology have been
described in detail previously (21). In short, 76%
completed the general health survey. We identified
subjects with CFH, defined as headache on
>14 days per month during the past 3 months, and
sent them a second, more detailed questionnaire
containing questions on comorbidity and quality of
life. Forty percent completed the questionnaire.
Non-responders showed no relevant demographic
differences from the responders. A random sample
of subjects with infrequent headache (IH), defined
as headache on 1–4 days per month, served as the
control group. The majority (62%) of subjects with
CFH overused acute headache medication. This
study was conducted before the publication of the
revised International Headache Society criteria for
medication overuse headache. We defined overuse
as: the use of analgesics on 3 days/week, the use
of triptans on 2 days/week, the use of ergots on
1 day/week or the use of narcotics on 10 days/
month. Overuse consisted mainly of analgesics,
only three (2%) overused triptans, one ergotamine
and seven (4%) narcotics.
Comorbidity was assessed by the following open
questions: (i) ‘Do you have a disorder for which
you have to consult your physician regularly?’; (ii)
‘Do you have other disorders for which regular
consultation is not necessary at the moment?’; (iii)
‘Have you been admitted to hospital in the past? If
yes, please specify’; (iv) ‘Which medication (includ-
ing painkillers) do you use?’. We recoded answers
by using the Cumulative Illness Rating Scale (CIRS)
(22). The CIRS is a reliable and validated comor-
bidity questionnaire and shows close resemblance
to common clinical practice: it is structured accord-
ing to 14 body systems and uses a clear severity
ranking that is clinically sound (23–27). The worst
problem in a specific organ system is rated on a
scale from 0 to 4 (0, none; 1, current mild problem
or significant problem in the past; 2, moderate
disability/requires daily medication; 3, severe/
constant disability, uncontrollable chronic problem;
and 4, extremely severe/immediate treatment
required/end organ failure/severe impairment in
function). Five summary scores can be calculated
[total CIRS score, total number of categories
endorsed, severity index (total score/total number
of categories) and number of level 3 and 4 severity]
(22). The total CIRS score was our main outcome
measure. Headache, our index disease, was not
rated as a comorbid disorder. Whenever the manual
of the CIRS was not clear about how to rate a
certain symptom or disease, we rated the symptom
by consensus and used a data file to record our
decisions. We modified the psychiatric illness rating
as follows: current usage of daily antidepressants or
anxiolytics without sleeping problems was rated as
severity 2, and psychiatric illness with daily use of
two medications as severity 3. Frequent sleeping
problems were listed under neurological comorbid-
ity, with occasional use of hypnotics as severity 1
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and daily use of hypnotics as 2. Use of benzodiaz-
epines without a specified indication was rated
according to their registered indication (e.g. diaz-
epam as anxiolytic).
Quality of life was measured by the RAND-36, a
Dutch version of the RAND-36-Item Short Form
Health Survey, a commonly used generic quality of
life questionnaire (28). The RAND-36 has been
shown to have excellent reliability and validity
when employed with diverse patient populations in
the Netherlands (29). It consists of eight domains of
well-being and functioning, including Physical
Functioning (PF), Social Functioning (SF), Physical
Role Functioning (PRF), Emotional Role Function-
ing (ERF), Mental Health (MH), Vitality (V), Bodily
Pain (BP) and General Health (GH), and an addi-
tional item, Health Transition (HT). The scales
range from 0 to 100, with higher scores indicating
better quality of life.
Data analysis was performed using SPSS 11.0
(SPSS Inc., Chicago, IL, USA). Differences are pre-
sented with 95% confidence intervals (95% CI).
Differences in comorbidity categories and quality of
life domains between CFH subjects and IH subjects
were tested for significance. Due to multiple com-
parisons we applied a Bonferroni adjustment yield-
ing an a level of 0.003 for the CIRS categories and
0.006 for the RAND-36 domains (30). The relation-
ship between RAND-36 scores and CIRS scores was
investigated using Spearman’s rank order correla-
tion. Values between 0.10 and 0.29 were considered
to indicate a weak correlation, between 0.30 and
0.49 a medium strong correlation and between 0.50
and 1.0 a strong correlation. Hierarchical multiple
regression was used to examine the relationship
between each RAND-36 domain and headache fre-
quency (case status) while controlling for educa-
tional level and CIRS score.
Results
Table 1 shows the demographic characteristics of
both headache groups. The CFH group had more
subjects with a lower educational level. The
presence of comorbidity is summarized in Table 2.
One CFH subject did not complete the comorbidity
section of the questionnaire and was excluded from
analysis. In both headache groups, the majority
currently had or had had in the past at least one
comorbid problem. Of 149 CFH subjects with any
comorbidity, 60% had a severity level of at least 2,
indicating disorders requiring daily medication
(e.g. hypertension).
In both groups the most prevalent comorbid
disorders were in the gastrointestinal and
musculosketal/skin categories. In the CFH group
21 of 24 subjects (88%) with upper gastrointestinal
problems reported heartburn, 19 used antacids or
acid suppressants, six of them in combination with
non-steroidal anti-inflammatory drugs (NSAIDs). In
the IH group four of seven subjects (57%) used acid
suppressants. Lower gastrointestinal problems were
mainly appendectomies in the past—16 (9%) CFH,
five (4%) IH; or other operations—seven (4%) CFH,
seven (5%) IH. In the musculoskeletal/skin cat-
egory, joint operations in the past—19 (11%) CFH,
14 (10%) IH, and arthritis; 10 (6%) CFH, five (4%)
IH were the most commonly reported disorders,
followed by back pain—nine (5%) CFH, six (4%) IH;
and neck pain/whiplash—seven (4%) CFH, 0 IH.
Six CFH subjects (3%) reported fibromyalgia, none
in the IH group. Dermatological disorders were
reported only once in the CFH group and four
times in the IH group.
CFH subjects had more endocrine/breast, psychi-
atric and neurological pathology than the IH sub-
jects. The endocrine/breast group consisted of a
sum of several disorders: thyroid pathology, diabe-
tes and breast cancer. In the psychiatry group, the
following comorbid problems contributed most
to the ratings: depressive mood or current use
of antidepressants—11 (6%) CFH, two (1%) IH;
anxiety disorder or current use of anxiolytics—13
(7%) CFH, three (2%) IH; current use of both anti-
depressants and anxiolytics—five (3%) CFH, one
(0%) IH. The differences in neurological ratings
were mainly due to sleeping problems or current
use of hypnotics—22 (13%) CFH, nine (6%) IH.
Table 1 Demographic characteristics of CFH and IH groups
CFH
N = 177
IH
N = 141
Difference,
% (95% CI)
Mean age, years (SD) 43 (8.4) 42 (8.0) 0.5 (-1.5, 2.4)
Female, n (%) 125 (72) 97 (70) 2% (-8, 12)
Low educational level, n (%) 62 (35) 16 (11) 24% (15, 33)
CFH, Chronic frequent headache (>14 days/month); IH, infrequent headache (1–4 days/month).
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Other reported disorders were epilepsy—six (3%)
CFH; hernia—five (3%) CFH, three (2%) IH; and
miscellaneous disorders—eight (5%) CFH, six (4%)
IH. In both psychiatric and endocrine/breast cat-
egories the difference between CFH subjects and IH
subjects was significant at the adjusted a level of
0.003, but not in the gastrointestinal, musculoskel-
etal and neurological categories.
CFH subjects had higher total CIRS scores than
IH subjects (Table 3). Median number of categories
endorsed was two in the CFH group vs. one in the
IH group. CFH was associated with a CIRS comor-
bidity level of at least 2 with a crude odds ratio of
2.6 (95% CI 1.6, 4.2), and adjusted for educational
level 2.2 (95% CI 1.3, 3.5). In the CFH group over-
users had higher total CIRS scores than non-
overusers (Table 4), but severity was not
significantly higher.
Quality of life of CFH subjects was lower in all
domains of the RAND-36 compared with the IH
subjects (Fig. 1). Scores for Health Transition were
45.2 in the CFH group and 54.6 in the IH group,
mean difference -9.4 (95% CI -14.3, -4.5). Small
differences in quality of life between subjects who
overused acute headache medication and those
who did not were not statistically significant
(Fig. 2). All domains of the RAND-36 were nega-
tively correlated with CIRS score (Table 5). Hierar-
chical multiple regression showed that after
controlling for educational level and CIRS score,
Table 2 Presence of comorbidity in the CFH group vs. IH group
CFH, n = 176 IH, n = 141 Difference, % (95% CI)
Presence of any comorbidity 149 (85) 91 (65) 20 (11, 29)*
Comorbidity with severity level 2 88 (50) 39 (28) 22 (12–33)*
Comorbidity with severity level 3 29 (17) 13 (9) 7 (0, 15)
Comorbidity categories endorsed*
Heart 6 (3) 3 (2) 1 (-2, 5)
Vascular 24 (14) 17 (12) 2 (-6, 9)
Haematopoietic 4 (2) 2 (1) 1 (-2, 4)
Respiratory 19 (11) 7 (5) 6 (0, 12)
Eyes, ears, nose and throat 33 (19) 19 (14) 5 (-3, 14)
Gastrointestinal 54 (31) 23 (16) 14 (5, 24)*
Upper gastrointestinal 24 (14) 7 (5) 9 (2, 15)*
Lower gastrointestinal 37 (21) 16 (11) 10 (1, 18)*
Liver 7 (4) 2 (1) 3 (-1, 6)
Renal 4 (2) 4 (3) -1 (-4, 3)
Genitourinary 24 (14) 16 (11) 2 (-5, 10)
Musculoskeletal/skin 60 (34) 32 (23) 11 (1, 21)*
Neurological 41 (23) 18 (13) 11 (2, 19)*
Endocrine/breast 21 (12) 3 (2) 10 (4, 16)*†
Psychiatric 33 (19) 8 (6) 13 (6, 20)*†
Values are n (%).
*95% CI excludes the neutral value of no difference (0%).
†Bonferroni: P < 0.003.
CFH, Chronic frequent headache; IH, infrequent headache.
Table 3 CIRS scores
CFH, n = 176 IH, n = 141 Difference (95% CI)
Total CIRS score 2.94 (2.52) 1.54 (1.75) 1.40 (0.91, 1.89)
Number of categories endorsed 1.92 (1.42) 1.10 (1.10) 0.82 (0.54, 1.11)
Severity index 1.47 (0.48) 1.36 (0.51) 0.11 (-0.02, 0.23)
Comorbidity with severity level 3, n (%) 27 (15) 13 (9) 6% (-1, 14)
Comorbidity with severity level 4, n (%) 2 (1) 0 (0) 1% (-1, 3)
Values are means (SD), unless stated otherwise.
CIRS, Cumulative Illness Rating Scale; CFH, chronic frequent headache; IH, infrequent headache.
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CFH case status remained an independent predictor
of all RAND-36 domains. Case status explained 5%
(Emotional Role Functioning) to 25% (Bodily Pain)
of the variance.
Discussion
To the best of our knowledge, the overall comor-
bidity of CFH has not previously been studied
systematically in a population-based sample. Sub-
jects with CFH reported more somatic and psychi-
atric comorbidity than subjects with infrequent
headaches. Overusers reported more comorbidity
than non-overusers. Fifty percent of the CFH sub-
jects had a comorbid problem causing at least
moderate disability or requiring daily medication
(severity level 2).
The CIRS is meant to give a global estimate of
medical burden taking into account both the pres-
ence and the severity of disorders. Its accuracy
depends on the ability of subjects to report diseases.
Self-reports have proven to be reasonably accurate
for estimations of prevalent health conditions (24,
31). The number of comorbid problems in our study
was lower than reported in other studies using the
CIRS (24, 25). This is probably due to the lower
mean age of our participants and the population-
based setting. We think our results are a reliable
estimate of the overall prevalence of comorbidity in
headache patients in the general population.
Twenty-eight percent of subjects in the IH group
had a comorbid disorder of at least severity level 2.
This is in accordance with another study conducted
in the Netherlands (32), where the prevalence of
Table 4 CIRS scores in overusers compared with non overusers
Overuse, n = 109 No overuse, n = 67 Difference, (95% CI)
Total CIRS score 3.34 (2.62) 2.28 (2.21) 1.06 (0.30, 1.81)
Number of categories endorsed 2.11 (1.43) 1.60 (1.35) 0.51 (0.08, 0.94)
Severity index 1.51 (0.50) 1.38 (0.44) 0.13 (-0.03, 0.29)
Comorbidity severity level 2, n (%) 61 (56) 27 (40) 16% (0, 31)
Comorbidity severity level 3, n (%) 21 (24) 6 (9) 15% (-1, 14)
Comorbidity severity level 4, n (%) 2 (2) 0 (0) 2% (-1, 5)
Values are means (SD), unless stated otherwise.
CIRS, Cumulative Illness Rating Scale.
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Figure 1 Mean RAND-36 scores (28) in the chronic
frequent headache (CFH, ) (n = 173) and infrequent
headache (IH, ) (n = 141) groups. CFH differs
significantly from IH in all domains (P < 0.001). PF,
Physical functioning; SF, social functioning; PRF, physical
role functioning; ERF, emotional role functioning; MH,
mental health; V, vitality; BP, bodily pain; GH, general
health.
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Figure 2 Mean RAND-36 scores (28) in the chronic
frequent headache (CFH) group with (, n = 107) and
without (, n = 66) overuse of acute headache medication.
Differences are not statistically significant. PF, Physical
functioning; SF, social functioning; PRF, physical role
functioning; ERF, emotional role functioning; MH, mental
health; V, vitality; BP, bodily pain; GH, general health.
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two or more co-occurring chronic or recurrent dis-
eases within one person in general practice was
29.7%.
Musculoskeletal problems were frequently
reported. Although not significant after Bonferroni
correction, chronic pain conditions tended to be
present more frequently in CFH than in IH subjects.
Headache has been associated with musculoskeletal
pain in the general population before; migraine was
associated with chronic back pain, and low back
pain in adolescents with headache (15, 33). In a
headache clinic, Peres et al. diagnosed fibromyalgia
in 36% of chronic migraine patients (16). Although
we did not find such a high prevalence, six CFH
subjects reported fibromyalgia vs. none in the IH
group. Central sensitization, a pathological change
in central pain processing, could play a role in the
co-occurrence of these chronic pain conditions (34).
Many CFH subjects reported gastrointestinal
problems. Heartburn, a symptom of gastro-
oesophageal reflux disease, was the most frequently
reported upper gastrointestinal disorder. It is a
common health problem and has considerable
impact on quality of life (35). Heartburn in the CFH
group could not be attributed entirely to NSAID
gastropathy since only 25% of CFH subjects with
heartburn used NSAIDs. The higher gastrointesti-
nal comorbidity in CFH subjects compared with IH
subjects might reflect a higher anxiety and per-
ceived stress level in CFH subjects (36).
The prevalence of psychiatric disorders in CFH in
the general population has never been studied. In
the elderly in Taiwan, CFH was associated with
high scores on a depression scale (12). Studies in
headache clinics have shown that CFH was associ-
ated with depression and anxiety disorders (7–9). It
was not surprising, therefore, to find more psychi-
atric pathology in the CFH group than in the IH
group. However, the percentage of subjects with
psychiatric comorbidity in the CFH group was
lower than expected. We previously found that the
majority of our CFH subjects screen positive for
psychopathology on the General Health Question-
naire (21). The prevalence of self-reported psychi-
atric comorbidity may have been underestimated
due to hesitation to report psychiatric problems or
simply because they may not yet have been diag-
nosed. The true prevalence of psychiatric disorders
can be assessed only by an interview based on
Diagnostic and Statistical Manual of Mental Disor-
ders (DSM) criteria.
Endocrine/breast disorders were present more
frequently in the CFH group than in the IH group.
The endocrine/breast category consisted of various
disorders, the numbers being too small for mean-
ingful subanalyses.
The RAND-36 scores in the IH group were
similar to normal values. Quality of life is clearly
impaired in the CFH group. Physical Role Func-
tioning and Vitality scored the lowest. The differ-
ence between CFH and IH was most marked for
Physical Role Functioning and Bodily Pain. The
Physical Role Functioning domain measures
whether one cannot fulfil one’s role/work because
of a physical problem. Considering the high preva-
lence of CFH, the low score in this particular
domain implies that CFH not only affects a subject’s
personal life but also has a major impact on society.
Our results are comparable to those of other
studies. In Spain, two studies found similar
decreases of quality of life measured with the SF-36
in subjects with CFH in the general population.
Both Colas et al. and Guitera et al. found Physical
Role Functioning, Bodily Pain and Vitality to be the
most affected domains (19, 20). Guitera et al. also
found that subjects with analgesic overuse scored
lower than the non-overusers in all domains, espe-
cially Physical Functioning and Bodily Pain. In our
study the small differences between overusers and
non-overusers were not statistically significant,
indicating that overuse causes only minor to no
extra impairment. Both headache frequency and
comorbidity had a negative influence on quality of
life. Logically, headache frequency showed a strong
influence on Bodily Pain and CIRS score on General
Health.
A limitation of this study is that comorbidity
rating is based on open general questions on
comorbid disorders. If questions on specific symp-
toms, such as joint or back pain, had been included,
Table 5 Relationship between quality of life and
comorbidity
Quality of life: RAND-36
domains
Comorbidity: correlations
with CIRS score
Physical Functioning -0.47*
Social Functioning -0.29*
Physical Role Functioning -0.28*
Emotional Role Functioning -0.20*
Mental Health -0.24*
Vitality -0.31*
Bodily Pain -0.34*
General Health -0.50*
Values are Spearman’s r.
*P < 0.001.
CIRS, Cumulative Illness Rating Scale (22); RAND-36,
quality of life questionnaire (28).
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we assume that certain body systems (e.g. muscu-
loskeletal) might have scored higher. Our data also
lacked information on various objective parameters
such as body mass index and levels of serum
cholesterol and haemoglobin, data that would
surely have increased endocrine, vascular and hae-
matopoietic comorbidity scores. However, we did
not aim to find specific disease prevalence rates or
associations, but rather to form an impression of the
extent of comorbidity experienced by and thus
most likely proving burdensome to the headache
patient. Causal relationships cannot be proved by
this cross-sectional study.
In conclusion, CFH patients in the general popu-
lation have more somatic and psychiatric comor-
bidity than patients with infrequent headaches.
Many CFH patients have a comorbid chronic con-
dition requiring daily medication. Both high head-
ache frequency and comorbidity contribute to the
low quality of life in these patients. The relatively
high prevalence of CFH, the high comorbidity rate
and the low quality of life indicate that CFH is a
major health problem.
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